| Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind … HGM Heijerman, EF McKone, DG Downey, E Van Braeckel, SM Rowe, ... The Lancet 394 (10212), 1940-1948, 2019 | 1100 | 2019 |
| Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium JM Bryant, DM Grogono, D Rodriguez-Rincon, I Everall, KP Brown, ... Science 354 (6313), 751-757, 2016 | 551 | 2016 |
| The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers NJ Rowbotham, S Smith, PA Leighton, OC Rayner, K Gathercole, ... Thorax 73 (4), 388-390, 2018 | 248 | 2018 |
| Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis J Tam, EF Nash, F Ratjen, E Tullis, A Stephenson Cochrane Database of Systematic Reviews, 2013 | 171 | 2013 |
| Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis HL Barr, N Halliday, M Cámara, DA Barrett, P Williams, DL Forrester, ... European Respiratory Journal 46 (4), 1046-1054, 2015 | 128 | 2015 |
| The global impact of SARS-CoV-2 in 181 people with cystic fibrosis E McClenaghan, R Cosgriff, K Brownlee, S Ahern, PR Burgel, CA Byrnes, ... Journal of cystic fibrosis 19 (6), 868-871, 2020 | 108 | 2020 |
| Prevalence of dyslipidemia in adults with cystic fibrosis B Rhodes, EF Nash, E Tullis, PB Pencharz, M Brotherwood, A Dupuis, ... Journal of Cystic Fibrosis 9 (1), 24-28, 2010 | 101 | 2010 |
| Analysis of four diverse population groups indicates that a subset of cystic fibrosis mutations occur in common among Caucasians. GR Cutting, SM Curristin, E Nash, BJ Rosenstein, I Lerer, D Abeliovich, ... American journal of human genetics 50 (6), 1185, 1992 | 98 | 1992 |
| Correlation between genotype and phenotype in patients with cystic fibrosis A Hamosh, BJ Rosenstein, E Nash, SM Curristin, GR Cutting, M Macek Jr, ... New England Journal of Medicine, 1993 | 93 | 1993 |
| Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week … S Sutharsan, EF McKone, DG Downey, J Duckers, G MacGregor, E Tullis, ... The Lancet Respiratory Medicine 10 (3), 267-277, 2022 | 91 | 2022 |
| Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials G Davies, NJ Rowbotham, S Smith, ZC Elliot, K Gathercole, O Rayner, ... Journal of Cystic Fibrosis 19 (3), 499-502, 2020 | 85 | 2020 |
| Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators–an international survey EF Nash, PG Middleton, JL Taylor-Cousar Journal of Cystic Fibrosis 19 (4), 521-526, 2020 | 75 | 2020 |
| Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis JK Dowman, D Watson, S Loganathan, BK Gunson, J Hodson, DF Mirza, ... American Journal of Transplantation 12 (4), 954-964, 2012 | 60 | 2012 |
| Incidence of deep vein thrombosis associated with peripherally inserted central catheters in adults with cystic fibrosis EF Nash, EJ Helm, A Stephenson, E Tullis Journal of Vascular and Interventional Radiology 20 (3), 347-351, 2009 | 55 | 2009 |
| Chest wall motion analysis in healthy volunteers and adults with cystic fibrosis using a novel Kinect-based motion tracking system JM Harte, CK Golby, J Acosta, EF Nash, E Kiraci, MA Williams, ... Medical & biological engineering & computing 54, 1631-1640, 2016 | 52 | 2016 |
| Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis‐associated liver cirrhosis EF Nash, C Volling, CA Gutierrez, E Tullis, A Coonar, K McRae, ... Clinical transplantation 26 (1), 34-41, 2012 | 47 | 2012 |
| Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis EF Nash, A Coonar, R Kremer, E Tullis, M Hutcheon, LG Singer, ... Transplant Infectious Disease 12 (6), 551-554, 2010 | 46 | 2010 |
| Employment in adults with cystic fibrosis K Targett, S Bourke, E Nash, E Murphy, J Ayres, G Devereux Occupational medicine 64 (2), 87-94, 2014 | 44 | 2014 |
| Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND … PA Flume, RF Biner, DG Downey, C Brown, M Jain, R Fischer, ... The Lancet Respiratory Medicine 9 (7), 733-746, 2021 | 42 | 2021 |
| Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: a longitudinal study HL Barr, N Halliday, DA Barrett, P Williams, DL Forrester, D Peckham, ... Journal of Cystic Fibrosis 16 (2), 230-238, 2017 | 39 | 2017 |
